Skip to Main Content
Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 2016, Issue 1
December 2 2016
Issue Cover

Table of Contents

Ham-Wasserman Manuscript

Inherited thrombophilia: a double-edged sword
Saskia Middeldorp
View Articletitled, Inherited thrombophilia: a double-edged sword

AML According to WHO: Newer Approaches to Therapy

Acute promyelocytic leukemia: preventing early complications and late toxicities
Sameem Abedin,Jessica K. Altman
View Articletitled, Acute promyelocytic leukemia: preventing early complications and late toxicities
Treatment of blastic plasmacytoid dendritic cell neoplasm
Jill M. Sullivan,David A. Rizzieri
View Articletitled, Treatment of blastic plasmacytoid dendritic cell neoplasm
Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?
Michael Heuser
View Articletitled, Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?

An Update on White Blood Cell Disorders

Children with rare diseases of neutrophil granulocytes: from therapeutic orphans to pioneers of individualized medicine
Christoph Klein
View Articletitled, Children with rare diseases of neutrophil granulocytes: from therapeutic orphans to pioneers of individualized medicine
Autoimmune and other acquired neutropenias
Peter E. Newburger
View Articletitled, Autoimmune and other acquired neutropenias
Primary immune deficiencies with defects in neutrophil function
Mary C. Dinauer
View Articletitled, Primary immune deficiencies with defects in neutrophil function

Anemia in the Young and Old

Pure red cell aplasia
Robert T. Means, Jr
View Articletitled, Pure red cell aplasia
Single-dose intravenous iron for iron deficiency: a new paradigm
Michael Auerbach,Thomas Deloughery
View Articletitled, Single-dose intravenous iron for iron deficiency: a new paradigm
New challenges in evaluating anemia in older persons in the era of molecular testing
David P. Steensma
View Articletitled, New challenges in evaluating anemia in older persons in the era of molecular testing

Bone Marrow Failures

Aplastic anemia and clonal evolution: germ line and somatic genetics
Akiko Shimamura
View Articletitled, Aplastic anemia and clonal evolution: germ line and somatic genetics
Nontransplant therapy for bone marrow failure
Danielle M. Townsley,Thomas Winkler
View Articletitled, Nontransplant therapy for bone marrow failure
Transplantation for bone marrow failure: current issues
Régis Peffault de Latour
View Articletitled, Transplantation for bone marrow failure: current issues

Bone Marrow Transplant: Understanding and Improving the Risk-Benefit Ratio

Biologic vs physiologic age in the transplant candidate
Andrew S. Artz
View Articletitled, Biologic vs physiologic age in the transplant candidate
Can we make a better match or mismatch with KIR genotyping?
Rohtesh S. Mehta,Katayoun Rezvani
View Articletitled, Can we make a better match or mismatch with KIR genotyping?
Role of the intestinal mucosa in acute gastrointestinal GVHD
Jonathan U. Peled,Alan M. Hanash,Robert R. Jenq
View Articletitled, Role of the intestinal mucosa in acute gastrointestinal GVHD

Chronic Lymphocytic Leukemia

Sequencing of chronic lymphocytic leukemia therapies
Jacqueline C. Barrientos
View Articletitled, Sequencing of chronic lymphocytic leukemia therapies
Novel agents in chronic lymphocytic leukemia
Nicole Lamanna,Susan O’Brien
View Articletitled, Novel agents in chronic lymphocytic leukemia
Prognostication of chronic lymphocytic leukemia in the era of new agents
Barbara Eichhorst,Michael Hallek
View Articletitled, Prognostication of chronic lymphocytic leukemia in the era of new agents
Evidence-Based Mini-Review
First-line therapy for young patients with CLL
Nitin Jain,Susan O’Brien
View Articletitled, First-line therapy for young patients with CLL

Chronic Myeloid Leukemia

Molecular monitoring in chronic myeloid leukemia—how low can you go?
Susan Branford
View Articletitled, Molecular monitoring in chronic myeloid leukemia—how low can you go?
Chronic myeloid leukemia: sequencing of TKI therapies
Jorge Cortes,Hagop Kantarjian
View Articletitled, Chronic myeloid leukemia: sequencing of TKI therapies
The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors
Fabio Efficace,Laura Cannella
View Articletitled, The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors

Common Consults in Thrombosis

Thrombosis in the setting of obesity or inflammatory bowel disease
Steven R. Lentz
View Articletitled, Thrombosis in the setting of obesity or inflammatory bowel disease
Thrombosis and anticoagulation in the setting of renal or liver disease
Christine Ribic,Mark Crowther
View Articletitled, Thrombosis and anticoagulation in the setting of renal or liver disease
Thrombosis in the setting of cancer
Michael B. Streiff
View Articletitled, Thrombosis in the setting of cancer
Evidence-Based Mini-Review
Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer
Lisa Baumann Kreuziger,Michael Streiff
View Articletitled, Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer

Complement Disorders and Hematologic Consequences

Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria
Charles J. Parker
View Articletitled, Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria
Atypical hemolytic uremic syndrome
Vahid Afshar-Kharghan
View Articletitled, Atypical hemolytic uremic syndrome
Cold agglutinin disease
Sigbjørn Berentsen
View Articletitled, Cold agglutinin disease

Disorders of Hemostasis and Thrombosis in Women's Health

Congenital and acquired bleeding disorders in pregnancy
Terry B. Gernsheimer
View Articletitled, Congenital and acquired bleeding disorders in pregnancy
Heavy menstrual bleeding: work-up and management
Andra H. James
View Articletitled, Heavy menstrual bleeding: work-up and management
Venous thromboembolism and stroke in pregnancy
Kelley McLean,Mary Cushman
View Articletitled, Venous thromboembolism and stroke in pregnancy

Disorders of Platelet Number and Function in Systemic Diseases

Platelets in liver and renal disease
Michele P. Lambert
View Articletitled, Platelets in liver and renal disease
Platelets in infectious disease
Elizabeth Middleton,Matthew T. Rondina
View Articletitled, Platelets in infectious disease
Heparin-induced thrombocytopenia: research and clinical updates
Oluwatoyosi Onwuemene,Gowthami M. Arepally
View Articletitled, Heparin-induced thrombocytopenia: research and clinical updates

Follicular Lymphomas

Prognostic factors in follicular lymphoma: new tools to personalize risk
Carla Casulo
View Articletitled, Prognostic factors in follicular lymphoma: new tools to personalize risk
Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy?
Nathan Fowler
View Articletitled, Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy?
Novel agents in follicular lymphoma: choosing the best target
Laurie H. Sehn
View Articletitled, Novel agents in follicular lymphoma: choosing the best target

Genetic Susceptibility to Leukemias

Introduction to cancer genetic susceptibility syndromes
Rose B. McGee,Kim E. Nichols
View Articletitled, Introduction to cancer genetic susceptibility syndromes
Germ line mutations associated with leukemias
Christopher C. Porter
View Articletitled, Germ line mutations associated with leukemias
Discussing and managing hematologic germ line variants
Wendy Kohlmann,Joshua D. Schiffman
View Articletitled, Discussing and managing hematologic germ line variants

Hodgkin Lymphoma: Treatment Today and the Challenge for Tomorrow

Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?
Peter W. M. Johnson
View Articletitled, Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?
Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment
Flora E. van Leeuwen,Andrea K. Ng
View Articletitled, Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment
Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma
Craig Moskowitz
View Articletitled, Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma

Informed Decisions in Acute Myeloid Leukemia: Beyond Morphology and Cytogenetics

Fitness in the elderly: how to make decisions regarding acute myeloid leukemia induction
Arati V. Rao
View Articletitled, Fitness in the elderly: how to make decisions regarding acute myeloid leukemia induction
Mutations in AML: prognostic and therapeutic implications
Courtney D. DiNardo,Jorge E. Cortes
View Articletitled, Mutations in AML: prognostic and therapeutic implications
MRD in AML: does it already guide therapy decision-making?
Gert Ossenkoppele,Gerrit Jan Schuurhuis
View Articletitled, MRD in AML: does it already guide therapy decision-making?

Lymphoma: Challenges and New Directions

Diffuse large B-cell lymphoma: R-CHOP failure—what to do?
Bertrand Coiffier,Clémentine Sarkozy
View Articletitled, Diffuse large B-cell lymphoma: R-CHOP failure—what to do?
Primary central nervous system lymphoma
Tracy T. Batchelor
View Articletitled, Primary central nervous system lymphoma
Checkpoint inhibition and cellular immunotherapy in lymphoma
Premal Lulla,Helen E. Heslop
View Articletitled, Checkpoint inhibition and cellular immunotherapy in lymphoma
Evidence-Based Mini-Review
Management of primary central nervous system lymphoma in children
Lisa Giulino-Roth,Oussama Abla,Tracy T. Batchelor
View Articletitled, Management of primary central nervous system lymphoma in children

Managing Severe Thrombosis and Sequelae

Diagnosis of suspected venous thromboembolism
Clive Kearon
View Articletitled, Diagnosis of suspected venous thromboembolism
Risk stratification and management of acute pulmonary embolism
Cecilia Becattini,Giancarlo Agnelli
View Articletitled, Risk stratification and management of acute pulmonary embolism
The post-thrombotic syndrome
Susan R. Kahn
View Articletitled, The post-thrombotic syndrome

Mantle Cell Lymphoma

Frontline therapy and role of high-dose consolidation in mantle cell lymphoma
Simon Rule
View Articletitled, Frontline therapy and role of high-dose consolidation in mantle cell lymphoma
Treatment of the elderly patient with mantle cell lymphoma
Pierre Soubeyran,Rémy Gressin
View Articletitled, Treatment of the elderly patient with mantle cell lymphoma
Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment
Eva Hoster,Christiane Pott
View Articletitled, Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment
Evidence-Based Mini-Review
Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly
Marco Ruella,Pierre Soubeyran
View Articletitled, Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly

Mechanisms of Transfusion Alloimmunization

Understanding red blood cell alloimmunization triggers
Jeanne E. Hendrickson,Christopher A. Tormey
View Articletitled, Understanding red blood cell alloimmunization triggers
Cellular immune responses in red blood cell alloimmunization
James C. Zimring,Krystalyn E. Hudson
View Articletitled, Cellular immune responses in red blood cell alloimmunization
Immunoregulatory networks in sickle cell alloimmunization
Karina Yazdanbakhsh
View Articletitled, Immunoregulatory networks in sickle cell alloimmunization

Myelodysplastic Syndromes

Treatment of low-risk myelodysplastic syndromes
Valeria Santini
View Articletitled, Treatment of low-risk myelodysplastic syndromes
Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure
Hetty E. Carraway
View Articletitled, Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure
Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens
Wael Saber,Mary M. Horowitz
View Articletitled, Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens

Myeloma

Myeloma: management of the newly diagnosed high-risk patient
Angela Dispenzieri
View Articletitled, Myeloma: management of the newly diagnosed high-risk patient
Sequencing of nontransplant treatments in multiple myeloma patients with active disease
Andrew J. Yee,Noopur S. Raje
View Articletitled, Sequencing of nontransplant treatments in multiple myeloma patients with active disease
Role of stem cell transplant and maintenance therapy in plasma cell disorders
Philip L. McCarthy,Sarah A. Holstein
View Articletitled, Role of stem cell transplant and maintenance therapy in plasma cell disorders

Myeloma: Immunotherapy

Advances and practical use of monoclonal antibodies in multiple myeloma therapy
Hans C. Lee,Donna M. Weber
View Articletitled, Advances and practical use of monoclonal antibodies in multiple myeloma therapy
Cellular and vaccine immunotherapy for multiple myeloma
Alfred L. Garfall,Edward A. Stadtmauer
View Articletitled, Cellular and vaccine immunotherapy for multiple myeloma
Checkpoint inhibition in myeloma
Don M. Benson, Jr
View Articletitled, Checkpoint inhibition in myeloma

Myeloproliferative Neoplasms

Update from the latest WHO classification of MPNs: a user’s manual
Francesco Passamonti,Margherita Maffioli
View Articletitled, Update from the latest WHO classification of MPNs: a user’s manual
Myelofibrosis: to transplant or not to transplant?
Rebecca Devlin,Vikas Gupta
View Articletitled, Myelofibrosis: to transplant or not to transplant?
Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions
Jamile M. Shammo,Brady L. Stein
View Articletitled, Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions

Optimizing Treatments for High-Risk Acute Lymphoblastic Leukemia: What It Takes to Move the Needle

Ph-like acute lymphoblastic leukemia
Thai Hoa Tran,Mignon L. Loh
View Articletitled, Ph-like acute lymphoblastic leukemia
Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia
Noelle V. Frey,David L. Porter
View Articletitled, Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia
Treatment of older patients with acute lymphoblastic leukemia
Nicola Gökbuget
View Articletitled, Treatment of older patients with acute lymphoblastic leukemia

Pediatric Hematologic Malignancies

T-cell acute lymphoblastic leukemia
Elizabeth A. Raetz,David T. Teachey
View Articletitled, T-cell acute lymphoblastic leukemia
Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum
John T. Sandlund,Mike G. Martin
View Articletitled, Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum
Myelodysplastic and myeloproliferative disorders of childhood
Henrik Hasle
View Articletitled, Myelodysplastic and myeloproliferative disorders of childhood

Reversing Old and New Anticoagulants

Reversing vitamin K antagonists: making the old new again
Sabine Eichinger
View Articletitled, Reversing vitamin K antagonists: making the old new again
Reversal of direct oral anticoagulants: a practical approach
Andrew W. Shih,Mark A. Crowther
View Articletitled, Reversal of direct oral anticoagulants: a practical approach
What to do after the bleed: resuming anticoagulation after major bleeding
Daniel M. Witt
View Articletitled, What to do after the bleed: resuming anticoagulation after major bleeding

Sickle Cell Disease: Clinical Management

Sickle cell disease: when and how to transfuse
Jo Howard
View Articletitled, Sickle cell disease: when and how to transfuse
Prevention of central nervous system sequelae in sickle cell disease without evidence from randomized controlled trials: the case for a team-based learning collaborative
Michael R. DeBaun,Allison A. King
View Articletitled, Prevention of central nervous system sequelae in sickle cell disease without evidence from randomized controlled trials: the case for a team-based learning collaborative
Sickle cell disease: an inherited thrombophilia
Ted Wun,Ann Brunson
View Articletitled, Sickle cell disease: an inherited thrombophilia

Treatment of Congenital Bleeding Disorders

New therapies for hemophilia
Steven W. Pipe
View Articletitled, New therapies for hemophilia
Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches
Shannon L. Meeks,Glaivy Batsuli
View Articletitled, Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches
Treatment of rare factor deficiencies in 2016
Flora Peyvandi,Marzia Menegatti
View Articletitled, Treatment of rare factor deficiencies in 2016
Evidence-Based Mini-Review
What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?
Maissaa Janbain,Steven Pipe
View Articletitled, What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?

von Willebrand Disease: Rediscovering an Old Disease

What have we learned from large population studies of von Willebrand disease?
Robert R. Montgomery,Veronica H. Flood
View Articletitled, What have we learned from large population studies of von Willebrand disease?
Diagnosing von Willebrand disease: genetic analysis
Anne Goodeve
View Articletitled, Diagnosing von Willebrand disease: genetic analysis
New treatment approaches to von Willebrand disease
Michelle Lavin,James S. O’Donnell
View Articletitled, New treatment approaches to von Willebrand disease

When Antibody Response Goes Awry

Warm antibody autoimmune hemolytic anemia
Theodosia A. Kalfa
View Articletitled, Warm antibody autoimmune hemolytic anemia
Second-line therapies in immune thrombocytopenia
Rachael F. Grace,Cindy Neunert
View Articletitled, Second-line therapies in immune thrombocytopenia
Prevention of thrombosis in antiphospholipid syndrome
Wendy Lim
View Articletitled, Prevention of thrombosis in antiphospholipid syndrome
Evidence-Based Mini-Review
What is the role of hydroxychloroquine in reducing thrombotic risk in patients with antiphospholipid antibodies?
Tzu-Fei Wang,Wendy Lim
View Articletitled, What is the role of hydroxychloroquine in reducing thrombotic risk in patients with antiphospholipid antibodies?

Erratum

Dao K-HT, Tyner JW. What’s different about atypical CML and chronic neutrophilic leukemia? Hematology Am Soc Hematol Educ Program. 2015;2015:264-271.
View Articletitled, Dao K-HT, Tyner JW. What’s different about atypical CML and chronic neutrophilic leukemia? <em>Hematology Am Soc Hematol Educ Program.</em> 2015;2015:<span class="related-article">264-271</span>.
All Issues
Targeted medical therapies for vascular anomalies
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma
Transplant in ALL: who, when, and how?
Ph− ALL: immunotherapy in upfront treatment
Ph+ ALL: new approaches for upfront therapy
  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal